Clinical stage-depending decrease of NK cell activity in multiple myeloma patients

Medical Oncology

Volumn 24, Issue 3, 2007, Pages 312-317

  Jurisic, Vladimir ^c   Srdic, Tatjana ^b   Konjevic, Gordana ^b   Markovic, Olivera ^a   Colovic, Milica ^a  

^a Institute of Forestry   (Serbia)

^b INSTITUTE FOR ONCOLOGY AND RADIOLOGY OF SERBIA   (Serbia)

^c UNIVERSITY OF KRAGUJEVAC   (Serbia)

Author keywords

Bone marrow plasma cells; Clinical stage; LDH; Multiple myeloma; NK cell activity; Survival; VAD protocol

Indexed keywords

BETA 2 MICROGLOBULIN; CYTOKINE; IMMUNOGLOBULIN G; LACTATE DEHYDROGENASE;

ADULT; AGED; ARTICLE; CELL ACTIVITY; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ACTIVITY; FEMALE; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; INNATE IMMUNITY; MALE; MULTIPLE MYELOMA; NATURAL KILLER CELL; PHENOTYPE; PLASMA CELL; PRIORITY JOURNAL;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BETA 2-MICROGLOBULIN; BONE MARROW; DEXAMETHASONE; DOXORUBICIN; FEMALE; HUMANS; IMMUNITY, NATURAL; IMMUNOGLOBULINS; KILLER CELLS, NATURAL; L-LACTATE DEHYDROGENASE; LYMPHOCYTE COUNT; LYMPHOCYTE SUBSETS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM STAGING; STATISTICS, NONPARAMETRIC; VINCRISTINE;

EID: 36249011958     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12032-007-0007-y     Document Type: Article

References (26)

1. Lotsova E. Natural killer cells: immunobiology and clinical prospects. Cancer Invest 1991;9:173-84.
2. Robertson MJ, Ritz J. Biology and clinical relevance of human natural killer cells. Review article. Blood 1990;76:2421-51.
3. Konjevic G, Jurisic V, Banicević B, Spuzic I. Difference in NK cell activity between patients with non-Hodgkin's lymphoma and Hodgkin's disease. Br J Haematol 1999;104:144-51.
4. Konjevic G, Jurisic V, Spuzic I. Association of NK cell dysfunction with changes in LDH characteristics of peripheral blood lymphocytes (PBL) in breast cancer patients. Breast Cancer Res Treat 2001;66:255-63.
5. Smyth MJ, Thia KY, Cretney E, Kelly JM, Snook MB, Forbes CA, Scalzo AA. Perforin is a major contributor to NK cell control of tumor metastasis. J Immunol 1999;162:6658-62.
6. Whiteside T, Herberman R. The role of natural killer cells in immune surveillance of cancer. Curr Opin Immunol 1995;7:704-10.
7. Durie BMG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975;36:842-9.
8. Greipp PR, Kyle RA. Staging, kinetics, and prognosis of multiple myeloma. In: Wiernik P, Canelos G, Ducher J, Kyle R, editors. Neoplastic disease of the blood. New York: Churchill Livingstone; 1996. p. 537-59.
9. Sulica A, Metes D, Cherman M, Whiteside TL, Herberman RB. Divergent effects of Fcc RIII A on the functional activities of human natural killer cells in vitro. Eur J Immunol 1996;26:1199-203.
10. Che S, Huston DP. Natural killer cell suppression of IgM production. Nat Immunol 1994;13:258-63.
11. Farssanito MA, Silvestris F, Cafforio P, Silvestris N, Dammacco F. IgG M-components in multiple myeloma patients induce a down-regulation of natural killer cell activity. Int J Clin Lab Res 1997;27:48-54.
12. Costelo RT, Fauriat C, Sivory S, Marcenaro E, Olive D. NK cells: innate immunity against hematological malignancies? Trends Immunol 2004;25:328-33.
13. Jurisic V, Spuzic I, Konjevic G. A comparison of NK cell activity with effects of TNF-a against K-562 cells, determined by LDH release assay. Cancer Lett 1999;138:67-72.
14. Jurisic V, Konjevic G, Jancic-Nedeljkov R, Sretenovic M, Banicevic B, Colovic M, Spuzic I. The comparison of spontaneous LDH release from cultured PBMC with sera LDH activity in Non-Hodgkin's lymphoma patients. Med Oncol 2004;21:179-85.
15. Jurisic V. Estimation of cell membrane alteration after drug treatment by LDH release. Blood 2003;101:2894.
16. Jurisic V, Colovic M. Correlation of sera TNF-alpha with percentage of bone marrow plasma cells, LDH, beta-2 microglobulin, and clinical stage in multiple myeloma. Med Oncol 2002;19(3):133-9.
17. Jurisic V, Bogdnovic G, Kojic V, Jakimov D, Srdic T. Effect of TNF-α on Raji cells at different cellular level estimated by various methods. Ann Hematol 2006;85:86-94.
18. Jurisic V, Kraguljac N, Konjevic G, Spuzic I. TNF-α induced changes in cell membrane antigen expression on K-562 cells is associated with increased LDH release. Neoplasma 2005;1:25-32.
19. Jurisic V, Bumbasirevic V, Konjevic G, Djuricic B, Spuzic I. TNF-α induced changes in LDH isotype profile following triggering of apoptosis in PBMC of non-Hodgkin's lymphoma. Ann Hematol 2004;83:84-91.
20. Ross ME, Caligiuri MA. Cytokine-induced apoptosis of human natural killer cells identifies a novel mechanism to regulate the innate immune response. Blood 1997;89:910-8.
21. Hallek M, Bergsagel PL, Anderson KC. Multiple myeloma: increasing evidence for a multiple transformation process. Blood 1998;91:3-21.
22. King MA, Radicchi-Mastroianni MA. Natural killer cells and CD56+ T cells in the blood of multiple myeloma patients: analysis by 4-color flow cytometry. Cytometry 1996;15:121-4.
23. Fauriat C, Mallet F, Olive D, Costello RT. Impaired activating receptor expression pattern in natural killer cells from patients with multiple myeloma. Leukemia 2006;20:732-3.
24. Carbone E, Neri P, Mesuraca M, Fulciniti MT, Otsuki T, Pende D, Groh V, Spies T, Poliio G, Cosman D, Catalano L, Tassone P, Rotoli B, Venuta S. HLA class I, NKG2D and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells. Blood 2005;105:251-8.
25. Von Lilienteld-Toal M, Nattermann J, Feldman G, Sievers E, Frank S, Strehl J, Schmidt-Wolf GH. Activated yd T cells express the natural killer cytotoxicity receptor natural killer p44 and show cytotoxic activity against myeloma cells. Clin Exp Immunol 2006;144:528-33.
26. Konjevic G, Jovic V, Jurisic V, Radulovic S, Jelic S, Spuzic I. IL-2 mediated augmentation of NK cell activity and activation antigen expression on NK and T cell subsets in metastatic melanoma patients treated with interferon alpha and DTIC. Clin Exp Metastasis 2003;20:647-55.